Mainz, Germany – In a significant shift for the biotechnology landscape, the co-founders of BioNTech, Professors Ugur Sahin and Özlem Türeci, are stepping down from their leadership roles to dedicate themselves to a fresh venture focused on next-generation mRNA innovations. This move, announced on March 10, 2026, signals a strategic realignment for both BioNTech and its visionary founders, aiming to accelerate advancements in mRNA technology and personalized medicine.
The husband-and-wife team, instrumental in the rapid development of the Pfizer-BioNTech COVID-19 vaccine, will establish an independent biotechnology company leveraging artificial intelligence (AI) to design and develop novel mRNA therapies. BioNTech will contribute related rights and mRNA technologies to the new company in exchange for a minority stake, according to a company statement. This strategic transition is designed to allow BioNTech to sharpen its focus on its growing late-stage clinical pipeline, which includes immunomodulators, antibody-drug conjugates, and other mRNA candidates.
A New Era of mRNA Innovation
Sahin and Türeci’s decision reflects a desire to explore the full potential of mRNA technology beyond its current applications. “We want to use our superpowers for medicine in a different way,” they stated, as reported by Euractiv. The new company will concentrate on developing next-generation mRNA innovations with disruptive potential, utilizing AI to accelerate the discovery and design of new therapies. This includes exploring applications in oncology, infectious diseases, and other areas of unmet medical need.
The transition is expected to be completed by the end of 2026, with ongoing clinical trials and data readouts remaining unaffected. BioNTech anticipates multiple late-stage data readouts throughout 2026, signaling continued progress in its existing clinical programs. The plan, as outlined in a BioNTech press release, is intended to maximize value for both patients and shareholders.
BioNTech’s Strategic Focus
With the founders’ departure to the new venture, BioNTech will concentrate on advancing its late-stage clinical pipeline. This includes a robust portfolio of immunomodulator, antibody-drug conjugate (ADC), and mRNA candidates. The company’s commitment to these areas reflects a strategic decision to build upon its existing strengths and deliver innovative therapies to patients. A binding agreement outlining the details of the new company’s formation is anticipated by mid-2026.
The move also highlights the growing importance of AI in drug discovery and development. By leveraging AI technologies, the new company aims to accelerate the identification of promising drug candidates and optimize their design for improved efficacy and safety. This approach has the potential to significantly reduce the time and cost associated with bringing new therapies to market.
Looking Ahead
The establishment of this independent biotechnology company represents a bold step forward in the field of mRNA technology. While BioNTech continues to advance its existing pipeline, the new venture, led by Sahin and Türeci, promises to unlock even greater potential for mRNA-based therapies. The impact of this strategic transition will be closely watched by the pharmaceutical industry and the medical community alike. The focus now shifts to the formalization of the agreement in mid-2026 and the subsequent launch of the new company’s research and development efforts.
What are your thoughts on the future of mRNA technology? Share your comments below, and please share this article with your network.
Disclaimer: This article provides informational content only and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions you may have regarding your health or treatment.
